HEMATOLOGY

Relapsed Chronic Lymphocytic Leukemia

Kerry A. Rogers, MD, discusses phase II findings with obinutuzumab, ibrutinib, and venetoclax and the future of dose-limited regimens in CLL.

In a merger agreement announced today, Bristol-Myers Squibb will be acquiring Celgene Corporation in a $74 billion deal to be paid with a combination of cash and stocks.

Dasatinib (Sprycel) tablets has been approved by the FDA to be used in combination with chemotherapy for the treatment of pediatric patients &ge;1 year of age with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.<br /> &nbsp;

A look back at all the&nbsp;FDA news&nbsp;that happened in the month of&nbsp;December 2018, including several new approvals, an accelerated approval, and a priority review.

John P. Leonard, MD, discusses the primary results from the randomized, double-blind phase III AUGMENT trial investigating the combination lenalidomide (Revlimid) plus rituximab (Rituxan) in patients with recurrent indolent lymphomas.

During a <em>Targeted Oncology</em> live case-based peer perspectives presentation, Jonathon B. Cohen, MD, MS, recently discussed the treatment considerations and decisions he makes when treating patients with classical Hodgkin Lymphoma

Andre Goy, MD, discusses the data presented at the 2018 ASH Annual Meeting for combination lenalidomide plus rituximab, also known as the R² regimen, for the treatment of patients with relapsed/recurrent follicular lymphoma.<br /> &nbsp;

Ravulizumab-cwvz has been approved by the FDA as an injection treatment for&nbsp;adults with paroxysmal nocturnal hemoglobinuria, a rare blood disorder that leads to hemolysis.

Several oncology experts discuss the FDA approvals they found most significant in 2018.

A longer-acting version of calaspargase pegol-mknl has been approved by the FDA&nbsp;as a component of a multiagent chemotherapy regimen for pediatric and young adult patients aged 1 month to 21 years with acute lymphoblastic leukemia.

Tagraxofusp-erzs infusion has been approved by the FDA for the treatment of adult and pediatric patients, aged &ge;2 years, with blastic plasmacytoid dendritic cell neoplasm.

Viola Poeschel, MD,&nbsp;discusses findings from the phase III FLYER trial and how they will impact the treatment landscape for younger patients with favorable-prognosis DLBCL.<br /> &nbsp;

According to findings from the&nbsp;phase IIb SADAL study, selinexor demonstrated deep and durable responses in patients with&nbsp;relapsed/refractory diffuse large B-cell lymphoma who are not candidates for autologous stem cell transplantation.

Victor A. Chow, MD, discusses findings of a retrospective study that looked at 55 patients with various B-cell lymphomas who progressed after treatment with CD19-specific CAR T cells.

The use of&nbsp;brentuximab vedotin in combination with chemotherapy has been recommended for approval by the&nbsp;European Medicines Agency&rsquo;s Committee for Medicinal Products for Human Use as a frontline treatment for&nbsp;adult patients with CD30+ stage IV Hodgkin lymphoma.

Sattva S. Neelapu, MD, discusses the main takeaway from 2-year follow-up data from the ZUMA-1 trial looking at axicabtagene ciloleucel in patients with refractory large B-cell lymphoma.

In findings reported during the 2018 ASH Annual Meeting,&nbsp;brentuximab vedotin with conventional chemotherapy significantly improved&nbsp;progression-free survival compared with standard therapy for nonpediatric patients&nbsp;with stage III/IV Hodgkin lymphoma.

Romiplostim has been granted FDA approval for the treatment of pediatric patients aged&nbsp;&ge;1 year with immune thrombocytopenia for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.